Literature DB >> 336377

Disposition of valproic acid in man.

R Gugler, A Schell, M Eichelbaum, W Fröscher, H U Schulz.   

Abstract

The pharmacokinetics of valproic acid (VPA) have been studied in 6 healthy subjects following a single 600 mg dose, and after multiple doses over 12 days (1200 mg daily) of enteric-coated sodium valproate. A time lag before absorption of 1 to 2 h was observed in each subject, and then absorption was rapid, peak concentrations being recorded 3 to 4 h after administration of the dose. The plasma level decline was biphasic with a terminal half-life of 15.9 +/- 2.6 h in the single dose and 17.3 +/- 3.0 h in the multiple dose experiments. There was no evidence of dose dependent kinetics or autoinduction. Total plasma clearance was 0.0064 +/- 0.0011 l/kg X h. The apparent volume of distribution was small at 0.15 +/- 0.2 l/kg. The mean steady state plasma concentration (Css) reached after 4 days was 81.3 +/- 13.0 microgram/ml. Css observed was lower than Css predicted (99.2 +/- 14.7 microgram/ml) from single dose kinetics (p less than 0.001). The difference was probably due to a reduction in plasma protein binding at higher concentrations. VPA concentration in saliva was between 0.4 and 4.5% of the total plasma concentration and was not equal to the concentration of unbound drug in plasma (6.7 +/- 0.8% unbound). 3.2% of the dose was excreted in urine as the parent drug and 21.2% as conjugated metabolites.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 336377     DOI: 10.1007/bf00645133

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Anticonvulsant level in saliva, serum, and cerebrospinal fluid.

Authors:  A S Troupin; P Friel
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

2.  [Pharmacodynamic properties of N-dipropylacetic acid].

Authors:  H MEUNIER; G CARRAZ; Y NEUNIER; P EYMARD; M AIMARD
Journal:  Therapie       Date:  1963 Mar-Apr       Impact factor: 2.070

3.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

4.  Decreased drug binding in serum from patients with chronic hepatic disease.

Authors:  S Wallace; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

5.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

6.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

7.  Controlled trial of sodium valproate in severe epilepsy.

Authors:  A Richens; S Ahmad
Journal:  Br Med J       Date:  1975-11-01

8.  Clinical trials of anti-epileptic drugs.

Authors:  H Meinardi
Journal:  Psychiatr Neurol Neurochir       Date:  1971 Mar-Apr

9.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

10.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

View more
  28 in total

1.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.

Authors:  Sabine Pilari; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-27       Impact factor: 2.745

Review 2.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 3.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

4.  Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients.

Authors:  G W Mihaly; F J Vajda; J L Miles; W J Louis
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

5.  Disposition of valproic acid in patients with liver disease.

Authors:  U Klotz; T Rapp; W A Müller
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

6.  Absorption rate and bioavailability of valproic acid and its sodium from rectal dosage forms.

Authors:  F Moolenaar; W J Greving; T Huizinga
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

Review 7.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 8.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

9.  First-dose and steady-state pharmacokinetics of valproic acid in children with seizures.

Authors:  K Hall; N Otten; J Irvine-Meek; M Leroux; D Budnick; M Verma; S S Seshia
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

10.  Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.

Authors:  Ehab S EL Desoky; Eliane Fuseau; Salah EL Din Amry; Valérie Cosson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.